Saxenda for Chronic Weight Management Now Available

April 22, 2015 3:50 PM

3 0

Saxenda for Chronic Weight Management Now Available

Novo Nordisk announced the launch of Saxenda (liraglutide [rDNA origin]) injection as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese) or ≥27kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia).

Saxenda is the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for this indication. Like endogenous GLP-1, liraglutide binds to and activates the GLP-1 receptor, a cell-surface receptor coupled to adenylyl cyclase activation through the stimulatory G-protein, Gs. GLP-1 is a physiolog...

Read more

To category page

Loading...